NINDS invites applications to develop, validate, and/or calibrate informative outcome measures for use in treatment trials for individuals with intellectual and developmental disabilities (IDD). This announcement is made together with 2 other NIH components.
Clinical trials are being designed that seek to alleviate the debilitating medical symptoms associated with IDD, such as Down syndrome, Fragile X syndrome, Rett syndrome, Angelman syndrome, Prader-Willi syndrome, and autism spectrum disorders. There is an urgent need to identify outcome measures that demonstrate treatment benefit for pharmacologic interventions or behavioral trials developed for use in these disorders, particularly in children. This initiative encourages the identification of endpoints for use in clinical trials of IDD therapies.
Potential applicants should contact Dr. Laura Mamounas, program director, Neurogenetics Cluster, NINDS, at 301-496-5745 or email@example.com. For more information visit http://grants.nih.gov/grants/guide/pa-files/PAR-11-045.html.